S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.68 (-0.41%)
MSFT   408.68 (+0.24%)
META   488.28 (+0.88%)
GOOGL   136.99 (+0.45%)
AMZN   174.87 (+0.99%)
TSLA   199.99 (-1.01%)
NVDA   792.25 (+2.01%)
NIO   5.68 (+4.60%)
AMD   186.78 (+5.80%)
BABA   74.22 (-0.50%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   89.66 (-0.06%)
CGC   3.32 (-1.19%)
GE   156.05 (+0.28%)
DIS   111.26 (+0.42%)
AMC   4.44 (-11.02%)
PFE   26.86 (-0.67%)
PYPL   60.76 (+0.85%)
XOM   104.72 (+0.38%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.68 (-0.41%)
MSFT   408.68 (+0.24%)
META   488.28 (+0.88%)
GOOGL   136.99 (+0.45%)
AMZN   174.87 (+0.99%)
TSLA   199.99 (-1.01%)
NVDA   792.25 (+2.01%)
NIO   5.68 (+4.60%)
AMD   186.78 (+5.80%)
BABA   74.22 (-0.50%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   89.66 (-0.06%)
CGC   3.32 (-1.19%)
GE   156.05 (+0.28%)
DIS   111.26 (+0.42%)
AMC   4.44 (-11.02%)
PFE   26.86 (-0.67%)
PYPL   60.76 (+0.85%)
XOM   104.72 (+0.38%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.68 (-0.41%)
MSFT   408.68 (+0.24%)
META   488.28 (+0.88%)
GOOGL   136.99 (+0.45%)
AMZN   174.87 (+0.99%)
TSLA   199.99 (-1.01%)
NVDA   792.25 (+2.01%)
NIO   5.68 (+4.60%)
AMD   186.78 (+5.80%)
BABA   74.22 (-0.50%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   89.66 (-0.06%)
CGC   3.32 (-1.19%)
GE   156.05 (+0.28%)
DIS   111.26 (+0.42%)
AMC   4.44 (-11.02%)
PFE   26.86 (-0.67%)
PYPL   60.76 (+0.85%)
XOM   104.72 (+0.38%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.68 (-0.41%)
MSFT   408.68 (+0.24%)
META   488.28 (+0.88%)
GOOGL   136.99 (+0.45%)
AMZN   174.87 (+0.99%)
TSLA   199.99 (-1.01%)
NVDA   792.25 (+2.01%)
NIO   5.68 (+4.60%)
AMD   186.78 (+5.80%)
BABA   74.22 (-0.50%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   89.66 (-0.06%)
CGC   3.32 (-1.19%)
GE   156.05 (+0.28%)
DIS   111.26 (+0.42%)
AMC   4.44 (-11.02%)
PFE   26.86 (-0.67%)
PYPL   60.76 (+0.85%)
XOM   104.72 (+0.38%)
NASDAQ:CNCR

Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$17.22
$17.71
50-Day Range
$27.45
$32.25
52-Week Range
$25.99
$35.82
Volume
70,558 shs
Average Volume
6,668 shs
Market Capitalization
$15.57 million
Assets Under Management
$19.44 million
Dividend Yield
1.68%
Net Expense Ratio
0.79%

About Range Cancer Therapeutics ETF

The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.


CNCR ETF News Headlines

Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
ETF S.S.-LONCAR CAN.I.ETF (E18B.BE)
12 Most Promising Cancer Stocks According to Analysts
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
See More Headlines
Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Exchange Traded Concepts
Fund Name
Range Cancer Therapeutics ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:CNCR
Inception Date
10/13/2015
Fund Manager
Denise M. Krisko
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Range Cancer Therapeutics Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
81

Fund Statistics

Assets Under Management
$19.44 million
Average Daily Volume
$487.40
Discount/Premium
0.11%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Exchange Traded Concepts, LLC
Custodian
U.S. Bank, N.A.
Distributor
Quasar Distributors, LLC
Transfer Agent
U.S. Bank, N.A.
Trustee
N/A
Lead Market Maker
Jane Street

Options

Optionable
N/A
Short Interest
26,800 shs

Miscellaneous

Beta
0.90
Creation Unit
50,000
Creation Fee
$150.00
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Range Cancer Therapeutics ETF Expenses

TypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.79%0.57%0.54%0.47%0.51%
Other Expenses0.00%0.40%0.55%0.33%0.58%
Total Expense0.79%0.72%0.70%0.57%0.70%
Fee Waiver0.00%-0.53%-0.55%-0.20%-0.57%
Net Expense0.79%0.61%0.60%0.53%0.58%

Range Cancer Therapeutics ETF (CNCR) Holdings & Exposure















CNCR ETF - Frequently Asked Questions

Are investors shorting Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF saw a increase in short interest in February. As of February 15th, there was short interest totaling 26,800 shares, an increase of 538.1% from the January 31st total of 4,200 shares. Based on an average daily volume of 9,200 shares, the short-interest ratio is presently 2.9 days.
View Range Cancer Therapeutics ETF's Short Interest
.

What does CNCR invest in?

Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $19.44 million assets under management.

What stocks does Range Cancer Therapeutics ETF hold?
What is the management fee for Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%.

What other stocks do shareholders of Range Cancer Therapeutics ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX).

Who are Range Cancer Therapeutics ETF's major shareholders?

Range Cancer Therapeutics ETF's stock is owned by a number of retail and institutional investors. Top institutional investors include OLD Mission Capital LLC (1.81%).

This page (NASDAQ:CNCR) was last updated on 2/29/2024 by MarketBeat.com Staff